Get started
Pfizer Inc.Pfizer Inc.Pfizer Inc.

Pfizer Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

$PFE - Watch for bounce at $43 or fall to $40.71 before reversal$PFE is at critical junction. If it can hold $43 and reverse, it will have formed double bottome. If it fails to hold $43 we could see 40.71 before attempting reversal. Entries - $43 - $40 (trickle in) Target -$52 Stop loss (for chickens) OR double down! (for brave hearts!) - below - $38 ——————————————————— How to read my charts? - Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines. - The yellow horizontal lines shows support and resistance areas. - Fib lines also shows support and resistance areas. - The dotted white lines shows price projection for breakout or breakdown target. Disclaimer: Do your own DD. Not an investment advice.
NYSE:PFELong
by PaperBozz
Pfizer dropping momentumFibgoals fractally at origin of Wave 5 of impulse and then beyond. If our mapping is correct, this impulse is done for now. Remember, this is not financial advice. You must do your own research and carefully make decisions for yourself by yourself. We love TA and do not provide individually tailored financial advice, or financial advice period. Now that aside, Fibonacci in crystal clear green and invalidation noted, as always, in red. Good luck out there.
NYSE:PFEShort
by Rykin_Capital
BULLISH IMPULSE IS COMING 💉✅PREVIOUSLY ON PFE We were expecting that A was broken and it's broken. ✅ WHERE WE ARE We have expected the drop to 43.27(Fib61.8). If the price is rejected around Fib61.8, we can expect the bullish impulsive wave. *As long as 37.96 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFELong
by waveslover
PFE Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NYSE:PFEShort
by hadimozayan
PFIZER Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NYSE:PFEShort
by hadimozayan
2
DROPPING WELL AS EXPECTED. READY FOR THE 3RD BOOST? 👁️ 💉✅PREVIOUSLY ON PFE We were expecting that A was broken and it's broken. ✅ WHERE WE ARE Because A is broken, it's confirmed that 47.50 is B. If so, we should recognize the C, at which bearish 5 waves would be formed after B. As of now, 43.27(Fib61.8) looks like the good long entry point to ride the next boost. *As long as 37.96 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFE
by waveslover
PFIZER: FUNDAMENTAL ANALYSIS + NEXT TARGET POINT ⚡️As you know, Pfizer's biggest product at the moment is the coronavirus vaccine, Comirnati. The company and its partner BioNTech expect it to bring in more than $33 billion this year. Meanwhile, Pfizer expects revenue from the coronavirus vaccine to account for 42% of the company's total revenue. The vaccine is certainly one good reason to buy stock in this major pharmaceutical giant. But there is another reason to buy Pfizer stock, and it has nothing to do with the COVID-19 vaccine. It is important to remember that Pfizer has a huge number of commercialized products, including seven blockbuster drugs. Earlier this month, one of them received good news - news that should prompt us to take a closer look at this pharmaceutical company's stock. Eliquis, the blood-thinning drug commercialized by Pfizer and its partner Bristol Myers Squibb, received a very important decision in the appeals court. The court upheld the original decision protecting the patents on this best-selling drug, including the drug's composition and formula. This means that the generic drugmaker will not be able to enter the market with a competing drug until April 2028. Pfizer and Bristol Myers will probably file another appeal, but after two courts have already ruled in their favor, one can be optimistic about their case. This is great news for Pfizer, given the revenue generated from the sale of the drug Eliquis. Last year, Pfizer reported more than $4.9 billion in revenue from the alliance and direct sales of the drug Eliquis. That's a 17% increase over the previous year. And this was during a pandemic when access to non-COVID health care was limited. Eliquis continues to be one of Pfizer's biggest drugs. In the second quarter of this year, Eliquis generated more than $1.4 billion in revenue. That's a 16% increase over the previous year, and Eliquis was Pfizer's second-largest drug after the coronavirus vaccine. Of course, generic competition will eventually lead to lower sales of this blockbuster drug. But the court ruling gives Pfizer seven years to develop products that can replace Eliquis as a major source of revenue. Pfizer has a lot of development going on. One of the most interesting candidates is an oral drug to treat the coronavirus. It would be a pill that people could take within days of the first symptoms, and it could be a game-changer and generate billions of dollars in revenue. Pfizer began Phase 2/3 trials in July and plans to present data in the fourth quarter. The company also recently began a Phase 3 trial of a vaccine candidate against respiratory syncytial infection. Currently, there is no vaccine against this common cause of severe respiratory disease. Should you buy Pfizer stock because of news about the Eliquis patent? It's not the only reason to buy the stock, but it's one great reason. Add to that the recurring earnings from the coronavirus program. And let's not forget the company's other blockbusters. Let's not forget the drugs and vaccines that could bring in a lot of revenue in the future. All of this together is a solid recipe for success over time. Pfizer stock is up 25% and is currently outperforming the S&P 500 Index. However, the stock is hardly reflective of all the positives now and in the future. They are trading at 11 times earnings estimates. By that measure, the stock is cheap today. Pfizer stock is far behind biotech players in the coronavirus vaccine space such as its own partner BioNTech and rival Moderna. You can't be sure that the situation will change. It's much easier to quickly raise the price of a company with less market value than a major pharmaceutical player. But over time, Pfizer has serious potential to increase revenues and profits -- and that should match the stock's rise. This month's news on the Eliquis patent is a huge step in the right direction.
NYSE:PFELong
by FOREXN1
4
$PFE - Key Levels and Analysis - REQUEST - I hold no position$PFE - Key Levels and Analysis ————— @Smartdaytrading, I think that PFE is overdue for a trip back toward the 180EMA(Purple)… Right now it is sitting right under the 35 EMA (Red) and this week if it closes under the gray line right under the red then I’d say watch for 41.64… that would be a good place to add if you’re long… The 35EMA has held as support for a large part of this year, but it tends to become resistance once it crosses down (and actually closes with the entire candle under the 35EMA)… and it’s been a little too long since it’s corrected back to the 180… Anything can happen... but I'd say keep a close eye on 41-42 area —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Red = Resistance Green = Support Blue = trendlines Have fun, y’all!!
NYSE:PFE
by SPYder_QQQueen_Trading
7
WE'D FACE THE BEARISH ABC CORRECTION 💉✅PREVIOUSLY ON PFE It can be thought that the 3rd wave finished at 51.86. ✅ WHERE WE ARE We could be on the correction waves. If 45.42 is A, the price falls to break A(45.42) After B hits. As of now, 43.27(Fib61.8) looks like the beginning of the next bullish impulse, circled 4. *As long as 51.86 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFEShort
by waveslover
2